1.9345

2.26% -0.0355

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $1.9345, with a volume of 4.20M. It is down -2.26% in the last 24 hours and down -15.18% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Previous Close:

$1.97

Open:

$2.1

24h Volume:

4.20M

Relative Volume:

1.82

Market Cap:

$681.55M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-5.5271

EPS:

-0.35

Net Cash Flow:

$-68.07M

1W Performance:

-7.43%

1M Performance:

-15.18%

6M Performance:

-35.39%

1Y Performance:

-13.66%

1-Day Range:

$1.92

$2.19

1-Week Range:

$1.89

$2.19

52-Week Range:

$1.67

$4.1598

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

(415) 754-3517

Address

357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO

Employee

203

Twitter

Next Earnings Date

2025-03-03

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB Nuvation Bio Inc	1.93	681.55M	0	-75.80M	-68.07M	-0.35
VRTX Vertex Pharmaceuticals Inc	488.57	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	687.75	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	635.59	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.34	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.72	27.34B	3.30B	-501.07M	1.03B	-2.1146

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-24	Upgrade	Jefferies	Hold → Buy
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

10:51 AM

Nuvation Bio to Receive Up to $250 Million in Funding From Sagard Healthcare Partners - Marketscreener.com

10:51 AM

10:48 AM

RBC bullish on Nuvation as royalty deal, non-dilutive financings remove overhang - TipRanks

10:48 AM

10:03 AM

Nuvation Bio nabs $250 million to launch cancer drug - The Pharma Letter

10:03 AM

09:31 AM

Nuvation Bio Secures Up To $250 Million In Non-Dilutive Financings From Sagard Healthcare Partners - Marketscreener.com

09:31 AM

09:15 AM

Nuvation Bio secures $250 million for cancer drug launch - Investing.com

09:15 AM

08:59 AM

Nuvation Bio secures up to $250M from Sagard Healthcare Partners; shares rise - MSN

08:59 AM

08:35 AM

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners - Business Wire

08:35 AM

Feb 27, 2025

Nuvation Bio (NUVB) to Release Earnings on Thursday - Defense World

Feb 27, 2025

Analyzing Sage Therapeutics (NASDAQ:SAGE) and Nuvation Bio (NYSE:NUVB) - Defense World

Feb 27, 2025

Feb 24, 2025

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference - BioSpace

Feb 24, 2025

Feb 20, 2025

Nuvation Bio Inc. (NYSE:NUVB) Short Interest Up 14.3% in January - MarketBeat

Feb 20, 2025

Feb 19, 2025

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - The Eastern Progress Online

Feb 19, 2025

Feb 18, 2025

What Do Wall Street Analysts Think About Nuvation Bio Inc (NYSE: NUVB) Stock? - Stocks Register

Feb 18, 2025

Peapod Lane Capital LLC Makes New $1.04 Million Investment in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Feb 18, 2025

Feb 17, 2025

Nuvation Bio executive departs after key milestones By Investing.com - Investing.com Nigeria

Feb 17, 2025

Feb 14, 2025

Nuvation Bio executive departs after key milestones - MSN

Feb 14, 2025

Feb 13, 2025

Nuvation BioPending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst (NUVB) - Seeking Alpha

Feb 13, 2025

Feb 12, 2025

Precision Underlines US FDA’s 2025 Cancer, Neuroscience Candidates - Citeline News & Insights

Feb 10, 2025

Feb 07, 2025

The Significance of Moving Averages in Nuvation Bio Inc Inc. (NUVB) Price Performance - The InvestChronicle

Feb 07, 2025